{"id":"NCT02638337","sponsor":"Shionogi","briefTitle":"Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Ospemifene in Patients With Moderate to Severe Vaginal Dryness, a Symptom of Vulvo-vaginal Atrophy (VVA) Due to Menopause","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-26","primaryCompletion":"2017-06-23","completion":"2017-07-05","firstPosted":"2015-12-23","resultsPosted":"2019-04-02","lastUpdate":"2019-04-02"},"enrollment":631,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Vaginal Dryness"],"interventions":[{"type":"DRUG","name":"Ospemifene","otherNames":["OsphenaÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ospemifene","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA.","primaryOutcome":{"measure":"Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Ospemifene","deltaMin":-23.7,"sd":1.4},{"arm":"Placebo","deltaMin":-1.9,"sd":1.4}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["37619252","30694917"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":317},"commonTop":["Hot flush","Upper respiratory tract infection","Urinary tract infection","Nasopharyngitis","Headache"]}}